CKD prevalence in elderly and the eGFR inflation effect, a very important paper in the @ndt-era.bsky.social . Not just for elderly but also for the young CKD population academic.oup.com/ndt/article/... #nephinp #nephrology_in_practice
Mo. Elrggal
@kidneyman.bsky.social
Nephrologist, 🇪🇬, Father, NSMC, NephJC, ISNACT, ISNGTF, NDTsocial, PLOSONE, ESNT, JHAH
A must read comprehensive article @ndt-era.bsky.social focusing on the biology/genetics of kidney stone. It highlights GWASs of calcium and phosphate handling (e.g., SLC34A1, CYP24A1, CaSR) and crystallization inhibitors (e.g., UMOD, pyrophosphate-related genes). academic.oup.com/ndt/article-...
large cohort study of CDK 4/6 BRAF EGFR VEGF and other cancer treatments #OncoNephrology #NephSky #KidneyWk jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial" Read more: kidney.pub/JASN0924
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. #KidneyWK @asnkidney.bsky.social ja.ma/4oV4DtU
In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters: bit.ly/3X1XpZj
Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation However, it moved nephrology forward and made studies happen lastmonthinnephrology.wordpress.com
Last Month in Nephrology
lastmonthinnephrology.wordpress.com
🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky @brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts *the original article from @asnpublications.bsky.social www.nephjc.com/news/nephjc-...
NephJC Shorts: MCD and FSGS Outcomes — NephJC
A NephJC Shorts discussion of the long term data on kidney failure in FSGS and MCD
nephjc.com
On 7/22/25 at 9pm EST only on Bluesky! #NephSky #MedSky join us for a lively discussion. We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC www.nephjc.com/news/egfrdiff
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
nephjc.com
Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com academic.oup.com/ndt/article/...
We don’t get to discuss every important study that comes out on #NephJC Hence #NephJCShorts www.nephjc.com/news/nephjc-...
Introducing NephJC Shorts — NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
nephjc.com
Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6...
Clinical Trials (ISN-ACT) - International Society of Nephrology
The ISN-Advancing Clinical Trials (ISN-ACT) is an ISN initiative to encourage existing infrastructures within ISN to improve the global nephrology community’s participation in clinical trial research.
lite.spr.ly
On the #AJKDBlog, catch up on these interviews with: - Oshozimhede E. Iyalomhe on statin use in CKD - Roger Rodby and William Whittier about renal tubular acidoses - Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia bit.ly/3ztk4VV (FREE)
Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky @uwmedicine.bsky.social youtu.be/TeWkmCopuzk
Kathy Tuttle, MD - New Approaches to Blocking Aldosterone & Angiotensinogen for Hypertension or CKD
YouTube video by University of Washington Division of Nephrology
youtu.be
When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM We get to see a CJASN abstract! From Divya Bajpai
📣 Reminder! ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait! 🗓 Applications close July 15, 2025. Click here to learn more: www.asdin.org/news/699844/... #vascularaccess #ASDIN #researchgrant #nephrology
Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org) #Nephpearls #NephSky 👉 kdigo.org/guidelines/a...
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/cjasn/abstra...
Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...
EU Approves Sparsentan for Treatment of IgAN | Docwire News
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy (IgAN).
docwirenews.com
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors jamanetwork.com/journals/jam...
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-an...
jamanetwork.com
Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD? #Nephpearls #AskRenal #NephSky ❤️ LIKE for YES (and why?) ❌ X for NO (and why?) 👉 pubmed.ncbi.nlm.nih.gov/39099568/
Do you allow hemodialysis patients with permanent HD catheters to shower? Yes No Other, please state www.ajkd.org/article/S027... #nephinp #nephrology_in_practice @ajkd.bsky.social
Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study
Patients on hemodialysis using a central venous catheter (CVC) are often advised not to shower due to infection risk. This study assessed practices and attitudes of patients and health care providers ...
ajkd.org
Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD doi.org/10.1016/j.kint.2025.02.018 Original article: doi.org/10.1016/j.kint.2025.01.023 #KICommentary #MedSky #NephSky #polycystickidneydisease
Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases? www.jci.org/articles/vie... #NephSky #MedSky
Journal of Clinical Investigation@jci.org · last yr.Aberrant activation of complement's alternative pathway may be the missing link in understanding how vascular and systemic inflammation accelerates chronic kidney disease progression. Read more in the review by Jalal, Thurman & Smith: buff.ly/DwHd0ut
Editorial by Harshil A. Fichadiya and John C. Lieske: Do Topiramate and Zonisamide Cause Kidney Stones? bit.ly/FichadiyaED25 (FREE)
#KIControversies in Nephrology Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients You can read the ✅Point ✅Counterpoint ✅Editor's summary in the May issue of KI doi.org/10.1016/j.kint.2025.01.039 #MedSky #NephSky #kidneytransplant
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases academic.oup.com/ndt/article/... An amazing article from the high impact articles published by @ndt-era.bsky.social
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical
academic.oup.com
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study bit.ly/3ZdrYxb #OpenAccess #VisualAbstract #CKD
